Is MRNA a Buy? What to Consider in 2026
Short answer
The bull case for Moderna (MRNA) rests on Respiratory franchise beyond COVID: Moderna is trying to convert a single-product COVID business into a broader respiratory portfolio. Q1 2026 revenue is ~$400 million. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs. Whether MRNA is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Moderna is a Cambridge, Massachusetts biotechnology company built entirely around messenger RNA (mRNA) technology, the platform behind its Spikevax COVID-19 vaccine. After generating enormous pandemic-era revenue, demand has fallen sharply, and the company is trying to broaden beyond COVID into a wider vaccine and therapeutics franchise. Its approved and near-market products include Spikevax, the mRESVIA RSV vaccine for older adults, and newer respiratory approvals in Europe (mNEXSPIKE and the mCOMBRIAX combination shot), while its most watched late-stage assets are the mRNA-1010 seasonal flu vaccine and intismeran autogene (mRNA-4157), a personalized cancer vaccine developed with Merck. The investment picture is a classic biotech turnaround. Q1 2026 revenue was roughly $400 million, up meaningfully year over year but tiny next to the pandemic peak, and the company posted a large net loss (heavily inflated by an ~$878 million legal settlement charge). Management guides to up to 10% revenue growth in 2026 and a cash flow break-even target by 2028, backed by a multibillion-dollar cash cushion. That leaves MRNA valued far more on future pipeline outcomes (flu approval, combination shots, and cancer-vaccine data) than on trailing financials, which is why the stock is volatile and closely tied to clinical and regulatory headlines.
What's the case for buying MRNA?
1. Respiratory franchise beyond COVID
Moderna is trying to convert a single-product COVID business into a broader respiratory portfolio. mRESVIA (RSV) is already approved for older adults, and Europe cleared mNEXSPIKE plus the mCOMBRIAX combination shot. A U.S. flu decision (mRNA-1010) with a PDUFA date around August 2026 is the next major catalyst, though the program has already had a regulatory setback.
2. Oncology optionality via Merck partnership
Intismeran autogene (mRNA-4157), the personalized cancer vaccine developed with Merck, is the highest-upside pipeline bet. Five-year Phase 2b adjuvant melanoma data showed a roughly 49% reduction in recurrence or death when combined with Keytruda versus Keytruda alone, and Phase 3 trials are expanding across melanoma, lung, bladder, and kidney cancers.
3. Cost discipline and a path to break-even
Management has framed 2026 around disciplined spending, targeting cash flow break-even by 2028 while preserving a large cash and investments balance (several billion dollars). International sales, including a U.K. government partnership, made up the bulk of recent revenue, which management points to as evidence of a more diversified base.
4. Platform leverage across many programs
Moderna carries one of the largest clinical-stage mRNA pipelines (dozens of candidates), spanning respiratory, latent viruses, rare diseases, and oncology. The thesis is that a single validated platform can produce multiple shots on goal, so a few approvals could re-rate the business even if individual programs fail.
What are the risks to MRNA?
Revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs. The company is loss-making and burning cash, making it dependent on pipeline approvals landing on schedule. Regulatory risk is concrete: the FDA issued a Refusal-to-File letter for the flu vaccine earlier in 2026, and shifting U.S. vaccine policy adds uncertainty. Large legal settlements (such as the Arbutus and Genevant charge) can swing reported results, and much of the long-term value depends on the Merck-partnered cancer vaccine succeeding in Phase 3, which is far from guaranteed.
How is MRNA valued? (as of July 2026)
Snapshot for MRNA as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Market cap: ~$20 billion
- Q1 2026 revenue: ~$400 million
- Q1 2026 net loss: ~$1.3 billion (incl. ~$878M legal charge)
- 2026 revenue growth guidance: up to ~10%
- Cash and investments: ~$7.5 billion (end of Q1 2026)
- Break-even target: cash flow break-even by ~2028
MRNA trades on pipeline potential rather than current earnings, since it is loss-making with revenue far below its pandemic peak. Traditional multiples like P/E are not meaningful while the company is unprofitable, so the market is effectively pricing the odds of flu, combination, and cancer-vaccine programs succeeding. The multibillion-dollar cash balance is a key reason the company can fund that pipeline toward its 2028 break-even goal.
How do you decide if MRNA is a buy?
Rather than asking whether MRNA is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold MRNA indirectly through an index or sector ETF before adding more.
For the full picture, see the MRNA stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about MRNA against your real portfolio and see your actual exposure before deciding.
The bottom line on MRNA
The bottom line: Moderna's story right now is Respiratory franchise beyond COVID, with q1 2026 revenue at ~$400 million. If you believe that narrative continues, the call is about sizing MRNA sensibly and checking overlap with what you own; if you doubt it (the risk: revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around MRNA with Walnut
Use Moderna as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is MRNA a good stock to buy right now?
+
The case for Moderna right now is Respiratory franchise beyond COVID, with q1 2026 revenue at ~$400 million. If you believe that thesis holds, MRNA is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Moderna do?
+
Moderna is a Cambridge, Massachusetts biotechnology company built entirely around messenger RNA (mRNA) technology, the platform behind its Spikevax COVID-19 vaccine.
What are the main risks of MRNA?
+
Revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs. The company is loss-making and burning cash, making it dependent on pipeline approvals landing on schedule. Regulatory risk is concrete: the FDA issued a Refusal-to-File letter for the flu vaccine earlier in 2026, and shifting U.S. vaccine policy adds uncertainty. Large legal settlements (such as the Arbutus and Genevant charge) can swing reported results, and much of the long-term value depends on the Merck-partnered cancer vaccine succeeding in Phase 3, which is far from guaranteed.
What does Moderna do?
+
Moderna is a biotechnology company that develops vaccines and therapeutics based on messenger RNA (mRNA). It is best known for its Spikevax COVID-19 vaccine and is now expanding into RSV, flu, combination respiratory shots, and cancer vaccines.
Is Moderna profitable?
+
No. As of mid-2026 Moderna is loss-making, reporting a net loss in Q1 2026 that was worsened by a large legal settlement charge. Management is targeting cash flow break-even by around 2028 through revenue growth and cost cuts.
How much revenue does Moderna make now?
+
Revenue has fallen sharply from its pandemic peak. Q1 2026 revenue was about $400 million, and management guides to up to roughly 10% revenue growth for the full year 2026, with a large share coming from international markets.
What is Moderna's most important pipeline product?
+
Two stand out: the mRNA-1010 seasonal flu vaccine, which had a U.S. regulatory decision expected around August 2026, and intismeran autogene (mRNA-4157), a personalized cancer vaccine developed with Merck that showed strong long-term melanoma data.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell MRNA; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.